Communications Medicine (Nov 2022)

Retrospective study of the immunogenicity and safety of the CoronaVac SARS-CoV-2 vaccine in people with underlying medical conditions

  • Chunmei Li,
  • Hanfang Bi,
  • Zhenwang Fu,
  • Ao Li,
  • Na Wan,
  • Jun Hu,
  • Fan Yang,
  • Tai-Cheng Zhou,
  • Yupeng Liang,
  • Wei Su,
  • Tianpei Shi,
  • Mei Yang,
  • Rong Wang,
  • Wanting Qin,
  • Xuanjing Yu,
  • Hong-Yi Zheng,
  • Zumi Zhou,
  • Yong-Tang Zheng,
  • Jia Wei,
  • Gang Zeng,
  • Zijie Zhang,
  • the Precise-CoVaccine study group

DOI
https://doi.org/10.1038/s43856-022-00216-2
Journal volume & issue
Vol. 2, no. 1
pp. 1 – 11

Abstract

Read online

Li et al. evaluate the immunogenicity and safety of the CoronaVac inactivated COVID-19 vaccine in elderly patients with underlying medical conditions in China. Most patients show comparable neutralizing antibody and SARS-CoV-2-specific T cell responses to healthy controls, and no serious adverse effects are seen.